Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Catalyst Pharma (CPRX)
NASDAQ:CPRX
CPRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$13.12 - $24.27
Previous CloseN/A
Volume328.11K
Average Volume (3M)1.23M
Market Cap
$2.69B
Enterprise Value$2.05B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)19.2
Beta1.01
Next Earnings
Mar 12, 2025EPS Estimate
0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.17
Shares Outstanding119,273,440
10 Day Avg. Volume1,712,523
30 Day Avg. Volume1,231,569
Standard Deviation0.14
R-Squared0.09
Alpha0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.84
Price to Cash Flow (P/CF)9.20
P/FCF Ratio9.30
Enterprise Value/Market Cap0.76
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit6.55
Enterprise Value/Ebitda10.67
Forecast
1Y Price Target
$31.67Price Target Upside40.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceCatalyst has delivered consistent double-digit year-over-year growth in Firdapse revenues.
Litigation OutcomesLupin's decision to change their Paragraph IV certifications for five of the six Firdapse Orange Book-listed patents to Paragraph III certifications is a positive indicator for the likely outcomes of the remaining cases.
Strategic InitiativesCatalyst is pursuing opportunities to expand their orphan disease portfolio by looking for an acquisition that is either accretive or nearly accretive, indicating active steps toward future growth.
Bears Say
Market CompetitionThe terms of the Teva deal were favorable to CPRX, calling for generic entry in 2035, but if other ANDA filers fail to reach similar agreements, competitive pressures may arise sooner.
Patent LitigationCatalyst is well-positioned for favorable outcomes in the unresolved litigation with Hetero and Lupin, and the Firdapse patents are expected to be upheld.
Revenue UncertaintyThere is significant potential for the expansion of Agamree to other orphan and rare diseases, but its future success is contingent on the company's ability to effectively penetrate these markets.
---
Ownership Overview
6.34% Insiders
17.43% Mutual Funds
0.36% Other Institutional Investors
48.79% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CPRX FAQ
What was Catalyst Pharma’s price range in the past 12 months?
Catalyst Pharma lowest stock price was $13.12 and its highest was $24.27 in the past 12 months.
What is Catalyst Pharma’s market cap?
Catalyst Pharma’s market cap is $2.69B.
When is Catalyst Pharma’s upcoming earnings report date?
Catalyst Pharma’s upcoming earnings report date is Mar 12, 2025 which is in 36 days.
How were Catalyst Pharma’s earnings last quarter?
Catalyst Pharma released its earnings results on Nov 06, 2024. The company reported $0.35 earnings per share for the quarter, beating the consensus estimate of $0.304 by $0.046.
Is Catalyst Pharma overvalued?
According to Wall Street analysts Catalyst Pharma’s price is currently Undervalued.
Does Catalyst Pharma pay dividends?
Catalyst Pharma does not currently pay dividends.
What is Catalyst Pharma’s EPS estimate?
Catalyst Pharma’s EPS estimate is 0.37.
How many shares outstanding does Catalyst Pharma have?
Catalyst Pharma has 119,273,440 shares outstanding.
What happened to Catalyst Pharma’s price movement after its last earnings report?
Catalyst Pharma reported an EPS of $0.35 in its last earnings report, beating expectations of $0.304. Following the earnings report the stock price went up 2.378%.
Which hedge fund is a major shareholder of Catalyst Pharma?
Among the largest hedge funds holding Catalyst Pharma’s share is Deerfield Management Company, LP. It holds Catalyst Pharma’s shares valued at 124M.
---
Catalyst Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$31.67 (40.38% Upside)
$31.67 (40.38% Upside)
Blogger Sentiment
Bullish
CPRX Sentiment 85%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 3.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 3.1%
Last 30 Days ▲ 3.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
54.45%
12-Months-Change
Fundamentals
Return on Equity
28.29%
Trailing 12-Months
Asset Growth
86.83%
Trailing 12-Months
Company Description
Catalyst Pharma
Catalyst Pharmaceuticals is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasmsThe company was founded Huckel E. Hubert in January 2002 and is headquartered in Coral Gables, FL.
---
CPRX Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented strong financial performance and positive growth, particularly with FIRDAPSE and AGAMREE. Despite a decline in FYCOMPA revenues and increased SG&A expenses, the company's overall financial position and strategic initiatives, including global expansion efforts, indicate a positive outlook.Read More>---
CPRX Stock 12 Month Forecast
Average Price Target
$31.67
▲(40.38% Upside)
Technical Analysis
Amgen
―
BioMarin Pharmaceutical
―
Regeneron
―
Vertex Pharmaceuticals
―
Ultragenyx Pharmaceutical
―
Best Analysts Covering CPRX
1 Year
1 Year Success Rate
16/19 ratings generated profit
1 Year Average Return
+32.79%
reiterated a buy rating 11 months ago
Copying Charles Duncan's trades and holding each position for 1 Year would result in 84.21% of your transactions generating a profit, with an average return of +32.79% per trade.
---